Experience
Genevant Sciences
Represented Genevant Sciences in negotiating and drafting several license and collaboration agreements for Genevant’s lipid nanoparticle technology, including agreements with Gritstone Oncology relating to COVID-19 and BioNTech relating to development of mRNA therapeutics for rare diseases.
Small molecule product development agreement for Roivant Sciences
Roivant Scientists
Finnegan tees up valuable patents for Eisai, leading to major strategic collaboration agreement
Eisai Co., Ltd.
BCL-2 inhibitors licensing agreement for Fochon Pharmaceuticals, Ltd.
Fochon Pharmaceuticals, Ltd.
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.